<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009446</url>
  </required_header>
  <id_info>
    <org_study_id>SNMM-SA-RTNeo</org_study_id>
    <nct_id>NCT05009446</nct_id>
  </id_info>
  <brief_title>Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM</brief_title>
  <acronym>SNMM</acronym>
  <official_title>A Prospective Single Arm Clinical Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced Sinonasal Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sinonasal mucosal melanoma (SNMM) is a very rare tumor, and SNMM is highly aggressive in&#xD;
      nature, with a 5-year survival rate of about 20~30%. Most patients underwent local recurrence&#xD;
      and distant metastasis within one or two years of treatment.&#xD;
&#xD;
      There is no unified standard for the treatment of SNMM.The principle of treatment for&#xD;
      surgically resectable stage T3 and partial T4 SNMM is complete resection of the primary&#xD;
      tumor, combined with postoperative radiotherapy. While locally unresectable SNMM has a poorer&#xD;
      prognosis, lower incidence, fewer clinical data have been reported.&#xD;
&#xD;
      This study will explore the role of preoperative radiotherapy and chemotherapy in improving&#xD;
      the 2-year OS rate, loco-regional control rate and distant metastasis rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2021</start_date>
  <completion_date type="Anticipated">August 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of first treatment until the date of death from any cause,through study completion,up to 2 years.</time_frame>
    <description>2 year Overall Survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of first treatment until the date of first documented progression or date of death from any cause, whichever came firstï¼Œthrough study completion,up to2 years</time_frame>
    <description>the date of first treatment to the first recording of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression free survival</measure>
    <time_frame>From date of first treatment to local failure or date of death from any cause,through study completion,up to 2 years</time_frame>
    <description>the date of first treatment to local failure or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional progression free survival</measure>
    <time_frame>From date of first treatment to regional failure or date of death from any cause, through study completion,up to 2 years</time_frame>
    <description>the date of first treatment to regional failure or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival</measure>
    <time_frame>From date of first treatment to distant metastasis or date of death from any cause, through study completion,up to 2 years</time_frame>
    <description>the date of first treatment to distant metastasis or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>From date of first treatment to the date of best overall response before surgery, assessed up to 6 months</time_frame>
    <description>objective remission rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Mucosal Melanoma</condition>
  <condition>Sinonasal Melanoma</condition>
  <arm_group>
    <arm_group_label>Preoperative radiotherapy and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative radiotherapy and chemotherapy plus endoscopic surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic surgery</intervention_name>
    <description>endoscopic surgery or endoscope-assisted surgery open surgery</description>
    <arm_group_label>Preoperative radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy</intervention_name>
    <description>radiotherapy was administrated before surgery</description>
    <arm_group_label>Preoperative radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy drug</intervention_name>
    <description>Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.</description>
    <arm_group_label>Preoperative radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age over 18 years old;&#xD;
&#xD;
          2. Pathologically confirmed with sinonasal mucosal melanoma;&#xD;
&#xD;
          3. Eligible for assessment by enhanced contrast computed tomography scan or magnetic&#xD;
             Resonance Imaging (MRI);&#xD;
&#xD;
          4. T4N0-1M0 according to the 8th edition American Joint Committee on Cancer (AJCC)&#xD;
             staging system, and breaks through the natural anatomical boundaries of orbital fascia&#xD;
             or dura mater; or 2) any Tumor stage, with retropharyngeal node metastasis.&#xD;
             unresectable tumor after multi-disciplinary team (MDT) discussion.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) score between 0 to 2;&#xD;
&#xD;
          6. No distant metastasis;&#xD;
&#xD;
          7. Adequate organ function;&#xD;
&#xD;
          8. Sign the informed consent forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There is evidence or suspicious of distant metastasis on clinical examination or&#xD;
             imaging examination;&#xD;
&#xD;
          2. suffered from uncontrolled concurrent diseases that may interfere with treatment;&#xD;
&#xD;
          3. Suffered from another malignant tumor or multiple primary tumors at the same time&#xD;
             within 5 years (excluding fully treated basal cell or squamous cell skin cancer,&#xD;
             cervical cancer in situ, etc.);&#xD;
&#xD;
          4. With surgical contraindications: severe cardiopulmonary disease, coagulation&#xD;
             dysfunction, etc;&#xD;
&#xD;
          5. With and conditions that interfere with patient compliance or safety;&#xD;
&#xD;
          6. With severe mental or neurological diseases;&#xD;
&#xD;
          7. Uncontrolled active infection diseases;&#xD;
&#xD;
          8. Pregnant or breastfeeding women;&#xD;
&#xD;
          9. Patients without personal freedom or independent civil capacity;&#xD;
&#xD;
         10. Other situations that are not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmeng Yu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye&amp; ENT Hospital of Fudan University, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaole Song, MD</last_name>
    <phone>15821388769</phone>
    <email>jxfxsxl@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye&amp; ENT Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weifang Wang</last_name>
      <phone>13916229507</phone>
    </contact>
    <investigator>
      <last_name>Xiaoshen Wang, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye &amp; ENT Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Hongmeng Yu</investigator_full_name>
    <investigator_title>Principal Investigator,Head of Rhinology</investigator_title>
  </responsible_party>
  <keyword>Sinonasal mucosal melanoma</keyword>
  <keyword>Inductive radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

